Skip to main content
Kangmei Pharmaceutical Co.,Ltd logo

Kangmei Pharmaceutical Co.,Ltd — Investor Relations & Filings

Ticker · 600518 ISIN · CNE0000017M1 LEI · 3003006FRNBUUTVKBB50 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,370 across all filing types
Latest filing 2025-07-04 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600518

About Kangmei Pharmaceutical Co.,Ltd

http://www.kangmei.com.cn

Kangmei Pharmaceutical Co.,Ltd. focuses on the research, development, production, and distribution of Traditional Chinese Medicine (TCM). The company manages an integrated industry chain that includes herbal cultivation, standardized processing of decoction pieces, and the manufacturing of patent medicines. Its offerings extend to health supplements, medical devices, and functional foods. A key component of its operations is the management of large-scale TCM trading centers and logistics hubs designed to standardize the trade of medicinal materials. Through its "Internet + Healthcare" initiatives, the company provides digital health management and pharmaceutical supply chain services, catering to medical institutions, retail pharmacies, and individual consumers.

Recent filings

Filing Released Lang Actions
广东信达律师事务所关于康美药业股份有限公司股权激励限制性股票回购注销实施的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the repurchase and cancellation of restricted stock under the company's equity incentive plans. It details the legal basis, decision procedures, disclosure, involved parties, share quantities, and cancellation date. The document is not a financial report, earnings release, or management discussion. It is a legal opinion related to a specific corporate action (stock repurchase and cancellation) and does not fit into categories like Annual Report, Interim Report, or Capital/Financing Update. It is not a simple announcement but a detailed legal opinion letter. Given the nature of the document as a legal opinion on a corporate action, it best fits under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and legal documents that do not fit other specific categories.
2025-07-04 Chinese
康美药业关于关联方收购公司债权被动形成关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a related party transaction involving the acquisition of company debt by an affiliated party. It details the transaction background, parties involved, transaction amount, and impact on the company. There are no financial statements or comprehensive financial data presented, nor is this a report or presentation. The document is a formal disclosure of a related party transaction, which fits best under Regulatory Filings (RNS) as it is a regulatory announcement about a corporate event that does not fall into other specific categories like capital update or management change.
2025-07-04 Chinese
康美药业关于子公司诉讼执行进展的公告（五）
Legal Proceedings Report Classification · 95% confidence The document is an announcement from 康美药业股份有限公司 regarding the progress of litigation involving its subsidiaries. It details court rulings, execution orders, and updates on the enforcement of judgments related to loan disputes and asset seizures. The text includes references to multiple prior announcements about the same litigation, indicating ongoing legal proceedings. There are no financial statements, earnings data, or management discussion of financial results. The document is a legal proceeding update rather than a full audit report or annual report. Therefore, it fits best under the category of Legal Proceedings Report (LTR). The document length is 2635 characters, which is typical for an announcement rather than a full report, but the content is substantive about legal matters, not just a brief notice or regulatory filing. Hence, the classification is LTR with high confidence.
2025-06-13 Chinese
康美药业关于召开2024年度暨2025年第一季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a performance explanation meeting (业绩说明会) for the 2024 annual and 2025 first quarter results. It provides the meeting time, location, participation method, and contact information. It references that the 2024 annual report and 2025 first quarter report have already been published on earlier dates. The document does not contain actual financial data or detailed financial analysis but serves to inform investors about the upcoming investor presentation event where these results will be discussed. Therefore, this document is best classified as an Investor Presentation (IP) announcement rather than the report itself or a simple report publication notice. The document length is short but contains detailed event information and interaction instructions, consistent with an Investor Presentation notice.
2025-05-15 Chinese
广东信达律师事务所关于康美药业股份有限公司2024年年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the legality and procedures of the 2024 Annual General Meeting (AGM) of 康美药业股份有限公司. It details the convening, attendance, voting procedures, and results of the AGM, including approval of various company reports and proposals. The document does not contain the actual annual report or financial statements but rather certifies the legality and validity of the AGM process and voting outcomes. This type of document is typically classified as Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results of the AGM.
2025-05-12 Chinese
康美药业2024年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2024 Annual General Meeting Resolution Announcement" for Kangmei Pharmaceutical Co., Ltd. It details the date and location of the AGM, attendance, voting results on various proposals including the 2024 annual report, profit distribution plan, financial statements, and other corporate matters. The document is a formal announcement of the voting results and resolutions passed at the AGM, including legal and procedural confirmations by lawyers. The document length is 3887 characters, which is relatively short and consistent with an announcement rather than a full report. It does not contain the full annual report or detailed financial statements but summarizes the resolutions and voting outcomes. Therefore, this document fits the category of "Declaration of Voting Results & Voting Rights Announcements" (DVA).
2025-05-12 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.